Lipocine Lied About Testosterone Pill's Chances, Investors Say
Lipocine Inc. misled investors by saying the U.S. Food and Drug Administration cleared its new testosterone drug when in fact the agency identified issues with the labeling, causing stock values to...To view the full article, register now.
Already a subscriber? Click here to view full article